Literature DB >> 19630774

Factor XI deficiency in animal models.

T Renné1, C Oschatz, S Seifert, F Müller, J Antovic, M Karlman, P M Benz.   

Abstract

The blood coagulation system forms fibrin to limit blood loss from sites of injury, but also contributes to occlusive diseases such as deep vein thrombosis, myocardial infarction, and stroke. In the current model of a coagulation balance, normal hemostasis and thrombosis represent two sides of the same coin; however, data from coagulation factor XI-deficient animal models have challenged this dogma. Gene targeting of factor XI, a serine protease of the intrinsic pathway of coagulation, severely impairs arterial thrombus formation but is not associated with excessive bleeding. Mechanistically, factor XI may be activated by factor XII following contact activation or by thrombin in a feedback activation loop. This review focuses on the role of factor XI, and its deficiency states as novel target for prevention of thrombosis with low bleeding risk in animal models.

Entities:  

Mesh:

Year:  2009        PMID: 19630774     DOI: 10.1111/j.1538-7836.2009.03393.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  15 in total

1.  Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Lawrence L Johnson; Erik I Tucker; Andras Gruber; David Gailani; Stephen T Smiley
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

Review 2.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

Review 3.  Factor XI and XII as antithrombotic targets.

Authors:  Felicitas Müller; David Gailani; Thomas Renné
Journal:  Curr Opin Hematol       Date:  2011-09       Impact factor: 3.284

4.  Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice.

Authors:  Philberta Y Leung; Sawan Hurst; Michelle A Berny-Lang; Norah G Verbout; David Gailani; Erik I Tucker; Ruikang K Wang; Owen J T McCarty; András Gruber
Journal:  Transl Stroke Res       Date:  2012-09       Impact factor: 6.829

Review 5.  Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?

Authors:  Becky Woodruff; Bruce Sullenger; Richard C Becker
Journal:  Curr Cardiol Rep       Date:  2010-07       Impact factor: 2.931

6.  A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits.

Authors:  Pancras C Wong; Earl J Crain; Carol A Watson; William A Schumacher
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

Review 7.  Polyphosphate as modulator of hemostasis, thrombosis, and inflammation.

Authors:  J H Morrissey; S A Smith
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

Review 8.  The search for new antithrombotic mechanisms and therapies that may spare hemostasis.

Authors:  Edward F Plow; Yunmei Wang; Daniel I Simon
Journal:  Blood       Date:  2018-02-21       Impact factor: 22.113

9.  Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation.

Authors:  Friederike Langhauser; Eva Göb; Peter Kraft; Christian Geis; Joachim Schmitt; Marc Brede; Kerstin Göbel; Xavier Helluy; Mirko Pham; Martin Bendszus; Peter Jakob; Guido Stoll; Sven G Meuth; Bernhard Nieswandt; Keith R McCrae; Christoph Kleinschnitz
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

10.  Targeting factor XI to prevent thrombosis.

Authors:  James H Morrissey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-07       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.